Patents by Inventor Noriko Koizumi
Noriko Koizumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9616101Abstract: The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.Type: GrantFiled: July 3, 2013Date of Patent: April 11, 2017Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Takahiro Nakamura, Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita, Kana Tominaga, Satoshi Kawasaki
-
Publication number: 20170002318Abstract: The present invention provides a method of culturing corneal endothelial cells. More specifically, the present invention provides a composition for culturing or growing corneal endothelial cells, comprising at least one agent consisting of laminins and fragments thereof which express in corneal endothelial cells. Specifically, the present invention can comprise laminin 511 (alpha5 beta1 gamma1) and laminin 512 (alpha5 beta2 gamma 1). The present invention further provides a culture container for corneal endothelial cells, which is coated with the composition of the present invention. Furthermore, the present invention provides a method for culturing corneal endothelial cells comprising the step of using the composition or the container of the present invention to culture the corneal endothelial cells.Type: ApplicationFiled: November 26, 2014Publication date: January 5, 2017Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA, Friedrich E. KRUSE, Ursula SCHLOETZER-SCHREHARDT
-
Publication number: 20160331736Abstract: Provided is an agent for treating or preventing a corneal endothelial disorder wherein cell proliferation is required. More specifically, provided is an agent for treating or preventing a corneal endothelial disorder, wherein cell proliferation is required, said agent comprising a p38MAP kinase inhibitor. In a preferred embodiment, the corneal endothelial disorder is a wound. In a preferred embodiment, the p38MAP kinase inhibitor is soluble in water. The p38MAP kinase inhibitor may comprise 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1H-imidazole-5-yl]pyridine (SB203580) or a salt thereof.Type: ApplicationFiled: November 13, 2014Publication date: November 17, 2016Applicant: The DoshishaInventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20160317528Abstract: The present invention provides an agent for treating or preventing a disease, a disorder or a condition of a corneal endothelium, said agent comprising a corneal endothelial cell and a myosin II-specific inhibitor. More specifically, the myosin II-specific inhibitor is blebbistatin. The disease, the disorder or the condition is typically a disorder associated with Fuchs endothelial corneal dystrophy or corneal endothelial dysfunction (bullous keratopathy). Also provided is a method for treating or preventing a corneal endothelial disease, said method comprising a step of administering an effective amount of a myosin II-specific inhibitor together with a corneal endothelial cell to a subject.Type: ApplicationFiled: December 27, 2013Publication date: November 3, 2016Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20160296505Abstract: The present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress. Specifically, the present invention provides a treatment drug or prophylactic drug for diseases, disorders, or conditions related to endoplasmic reticulum (ER) stress in the corneal epithelium, the drug containing a TGF?-signal inhibitor. As a preferred TGF?-signal inhibitor, the drug contains 4-[4-(1,3-benzodioxole-5-yl)-5-(2-pyridinyl)-1H-imidazole-2-yl]benzamide.Type: ApplicationFiled: October 30, 2014Publication date: October 13, 2016Applicants: Kyoto Prefectural Public University corporation, The Doshisha, Senju Pharmaceutical Co., Ltd.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20160266114Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.Type: ApplicationFiled: July 28, 2014Publication date: September 15, 2016Inventors: Noriko KOIZUMI, Naoki OKUMURA, Hiroatsu HIRANO, Shigeru KINOSHITA, Morio UENO
-
Publication number: 20160158210Abstract: The present invention provides medicaments for treating or preventing a disease, disorder, or condition associated with extracellular matrix (ECM) abnormality in a corneal endothelium, wherein the medicaments comprise a TGF-beta signal inhibiting agent. More specifically, this disease, disorder, or condition is a disorder associated with Fuchs' endothelial corneal dystrophy. Such a disorder includes photophobia, blurred vision, vision disorder, eye pain, lacrimation, hyperemia, pain, bullous keratopathy, ophthalmic unpleasantness, a decrease in contrast, glare, edema in corneal stroma, bullous keratopathy, corneal opacity, and the like. A preferable TGF-beta signal inhibiting agent includes 4-[4-(1,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide.Type: ApplicationFiled: July 30, 2013Publication date: June 9, 2016Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20160101113Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: October 9, 2015Publication date: April 14, 2016Inventors: Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO
-
Publication number: 20160030410Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: October 9, 2015Publication date: February 4, 2016Inventors: Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO
-
Patent number: 9248125Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: August 28, 2008Date of Patent: February 2, 2016Assignees: Senju Pharmaceutical Co., Ltd.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
Publication number: 20160008408Abstract: [Problem] To provide a method for producing human corneal epithelial sheet, wherein the human corneal epithelial-derived cells obtained by culturing human corneal epithelial cells are cultured on an amnion substrate. [Solution] A method for culturing human corneal epithelial cells using mesenchymal stem cells as the feeder cells; and a method for culturing human corneal epithelial cells using a medium containing a ROCK inhibitor, a phosphodiesterase inhibitor, a MAP kinase inhibitor and a TGF-? receptor inhibitor in various combinations.Type: ApplicationFiled: March 9, 2014Publication date: January 14, 2016Applicants: JCR PHARMACEUTICALS CO., LTD., KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Kiwamu IMAGAWA, Kenichi MAEDA, Yuki HOSODA, Shuichi YOKOYAMA, Naoki OKUMURA, Noriko KOIZUMI, Shigeru KINOSHITA
-
Publication number: 20150210981Abstract: [Problem] To provide, in order to manufacture cells to transplant into patients with corneal endothelial failure, a medium used to culture corneal endothelial cells obtained from human corneal tissue and grow said cells while maintaining the morphology thereof as corneal endothelial cells. [Solution] A medium containing a conditioned medium from mesenchymal stem cells; and a method in which said medium is used to culture corneal endothelial cells.Type: ApplicationFiled: September 5, 2013Publication date: July 30, 2015Inventors: Michio Hagiya, Kiwamu Imagawa, Yuuki Hosoda, Noriko Koizumi, Naoki Okumura, Makiko Nakahara, Shigeru kinoshita
-
Publication number: 20150202256Abstract: The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.Type: ApplicationFiled: July 3, 2013Publication date: July 23, 2015Applicants: Kyoto Prefectural Public University Corporation, Senju Pharmaceutical Co., Ltd., The DoshishaInventors: Takahiro Nakamura, Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita, Kana Tominaga, Satoshi Kawasaki
-
Publication number: 20150044178Abstract: The present invention provides a method for the normalized culturing of corneal endothelial cells. More specifically, the present invention provides a culture-normalizing-agent of a corneal endothelial cell, comprising a fibrosis inhibitor. In detail, the present invention provides a culture-normalizing agent comprising a transforming growth factor (TGF) ? signal inhibitor. The present invention also provides a culture medium for culturing a corneal endothelial cell normally, which comprises the culture-normalizing agent according to the present invention and corneal endothelium culture components. The present invention also provides a method for culturing a corneal endothelial cell normally, comprising the step of culturing a corneal endothelial cell using the culture-normalizing agent according to the present invention or the culture medium according to the present invention.Type: ApplicationFiled: December 27, 2012Publication date: February 12, 2015Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SENJU PHARMACEUTICAL CO., LTD., THE DOSHISHAInventors: Shigeru Kinoshita, Noriko Koizumi, Naoki Okumura
-
Patent number: 8895508Abstract: The present invention aims to provide a corneal endothelium cell proliferation accelerator and a therapeutic agent for a disease relating to corneal endothelium damage, which are administered into the anterior chamber. bFGF is released in a sustained manner by forming bFGF sustained-release gelatin hydrogel particles wherein bFGF is carried on gelatin hydrogel. Therefore, the proliferation of corneal endothelium cells can be accelerated persistently by administration of a preparation containing the bFGF sustained-release gelatin hydrogel particles into the anterior chamber, and diseases relating to corneal endothelium damage can be treated.Type: GrantFiled: July 24, 2009Date of Patent: November 25, 2014Assignees: Senju Pharmaceutical Co., Ltd.Inventors: Yasuhiko Tabata, Shigeru Kinoshita, Noriko Koizumi, Yuji Sakamoto, Naoki Okumura, Hiroaki Takahashi
-
Publication number: 20120190621Abstract: The present invention aims to provide a corneal endothelium cell proliferation accelerator and a therapeutic agent for a disease relating to corneal endothelium damage, which are administered into the anterior chamber. bFGF is released in a sustained manner by forming bFGF sustained-release gelatin hydrogel particles wherein bFGF is carried on gelatin hydrogel. Therefore, the proliferation of corneal endothelium cells can be accelerated persistently by administration of a preparation containing the bFGF sustained-release gelatin hydrogel particles into the anterior chamber, and diseases relating to corneal endothelium damage can be treated.Type: ApplicationFiled: July 24, 2009Publication date: July 26, 2012Applicants: SENJU PHARMACEUTICAL CO., LTD.Inventors: Yasuhiko Tabata, Shigeru Kinoshita, Noriko Koizumi, Yuji Sakamoto, Naoki Okumura, Hiroaki Takahashi
-
Publication number: 20100233240Abstract: The present invention provides a graft more suitable for the transplantation of corneal endothelial cells and an application method thereof. Specifically, the present invention provides a corneal endothelial preparation capable of cell proliferation in vivo, which contains a substrate and a corneal endothelial cell layer cultured on the substrate, and a treatment method of a disease selected from the group consisting of bullous keratopathy, corneal edema, corneal leukoma and corneal endothelial inflammation, which includes a step of transplanting the preparation to patients. As the substrate, collagen is used.Type: ApplicationFiled: January 18, 2007Publication date: September 16, 2010Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Yuji Sakamoto
-
Publication number: 20100209402Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: August 28, 2008Publication date: August 19, 2010Applicants: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno